Ehab Essawy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ehab Essawy has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Mansour El-Matbouli
Division of Fish Health, University of Veterinary Medicine, 1210 Vienna, Austria
2 shared publications - Mona Saleh
Department of Farm Animals and Veterinary Public Health, Division of Fish Health, University of Veterinary Medicine, 1210 Vienna, Austria
2 shared publications - Abdulaziz Abdulrahman Al Askar
Botany and Microbiology Department, Faculty of Science, King Saud University, Riyadh, Saudi Arabia
1 shared publication - Ahmed Abdelalim
Cairo University Stroke Center, Department of Neurology, Faculty of Medicine, Cairo University, Egypt (A.A., S.A., S.A.I.).
1 shared publication Ahmed E. Abdel Moneim
Unit of Scientific Research, Applied College , Qassim University , Saudi Arabia
1 shared publicationAhmed H. Elattar
Chemistry Department, Biochemistry Division, Faculty of Science , Helwan University , Cairo , Egypt
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Chemistry
- Vol. 24 (1)
Green-synthesized silver nanoparticles from Syzygium aromaticum extract promote cancer cell death by targeting redox and inflammatory pathways
Clove ( Syzygium aromaticum ) is a medicinal spice rich in bioactive compounds with potent antioxidant and therapeutic activities, making it a promising candidate for anticancer applications. Leveraging these properties, we synthesized green silver nanoparticles loaded with S. aromaticum extract (AgNPs-SAE) to enhance its antitumor potential. This study evaluated the efficacy of SAE and AgNPs-SAE in Ehrlich solid tumor (EST)-bearing mice, compared with doxorubicin (DOX). Forty mice were divided into four groups ( n = 10): untreated EST control, SAE (500 mg/kg, orally), AgNPs-SAE (30 mg/kg, orally), and DOX (10 mg/kg, i. p., for 3 days). In vitro , SAE and AgNPs-SAE exhibited cytotoxicity against NBL and MCF7 cells, with higher potency observed for AgNPs-SAE. In vivo , both SAE and AgNPs-SAE significantly reduced tumor growth, with tumor volumes decreased, compared to the untreated group, and extended survival compared to the untreated and DOX-treated groups. Unlike DOX, which elevated hepatic and renal biomarkers in the mouse model, SAE and AgNPs-SAE preserved organ function. These findings indicate that, in this preclinical study, SAE and AgNPs-SAE exhibit promising antitumor efficacy with reduced hepatorenal toxicity compared to DOX, supporting further investigation in preclinical models. Mechanistic analyses indicated that SAE and AgNPs-SAE exerted antitumor effects by reducing oxidative stress and inflammation, promoting apoptotic cell death, and inhibiting tumor cell proliferation, suggesting a multi-targeted mechanism of action. In conclusion, SAE and AgNPs-SAE demonstrate promising antitumor potential with fewer side effects than conventional chemotherapeutics like DOX. The enhanced efficacy of AgNPs-SAE underscores the advantage of combining phytochemicals with nanotechnology to develop safer and more effective cancer therapies.
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Chemistry
- Vol. 24 (1)
Open AccessGreen-synthesized silver nanoparticles from Syzygium aromaticum extract promote cancer cell death by targeting redox and inflammatory pathways
Clove ( Syzygium aromaticum ) is a medicinal spice rich in bioactive compounds with potent antioxidant and therapeutic activities, making it a promising candidate for anticancer applications. Leveraging these properties, we synthesized green silver nanoparticles loaded with S. aromaticum extract (AgNPs-SAE) to enhance its antitumor potential. This study evaluated the efficacy of SAE and AgNPs-SAE in Ehrlich solid tumor (EST)-bearing mice, compared with doxorubicin (DOX). Forty mice were divided into four groups ( n = 10): untreated EST control, SAE (500 mg/kg, orally), AgNPs-SAE (30 mg/kg, orally), and DOX (10 mg/kg, i. p., for 3 days). In vitro , SAE and AgNPs-SAE exhibited cytotoxicity against NBL and MCF7 cells, with higher potency observed for AgNPs-SAE. In vivo , both SAE and AgNPs-SAE significantly reduced tumor growth, with tumor volumes decreased, compared to the untreated group, and extended survival compared to the untreated and DOX-treated groups. Unlike DOX, which elevated hepatic and renal biomarkers in the mouse model, SAE and AgNPs-SAE preserved organ function. These findings indicate that, in this preclinical study, SAE and AgNPs-SAE exhibit promising antitumor efficacy with reduced hepatorenal toxicity compared to DOX, supporting further investigation in preclinical models. Mechanistic analyses indicated that SAE and AgNPs-SAE exerted antitumor effects by reducing oxidative stress and inflammation, promoting apoptotic cell death, and inhibiting tumor cell proliferation, suggesting a multi-targeted mechanism of action. In conclusion, SAE and AgNPs-SAE demonstrate promising antitumor potential with fewer side effects than conventional chemotherapeutics like DOX. The enhanced efficacy of AgNPs-SAE underscores the advantage of combining phytochemicals with nanotechnology to develop safer and more effective cancer therapies.
- Open Access
Exploring Exogenous Indole-3-acetic Acid’s Effect on the Growth and Biochemical Profiles of Synechocystis sp. PAK13 and Chlorella variabilis
Microalgae have garnered scientific interest for their potential to produce bioactive compounds. However, the large-scale industrial utilization of microalgae faces challenges related to production costs and achieving optimal growth conditions. Thus, this study aimed to investigate the potential role of exogenous indole-3-acetic acid (IAA) application in improving the growth and production of bioactive metabolites in microalgae. To this end, the study employed different concentrations of exogenously administered IAA ranging from 0.36 µM to 5.69 µM to assess its influence on the growth and biochemical composition of Synechocystis and Chlorella. IAA exposure significantly increased IAA levels in both strains. Consequentially, improved biomass accumulation in parallel with increased total pigment content by approximately eleven-fold in both strains was observed. Furthermore, the application of IAA stimulated the accumulation of primary metabolites. Sugar levels were augmented, providing a carbon source that facilitated amino acid and fatty acid biosynthesis. As a result, amino acid levels were enhanced as well, leading to a 1.55-fold increase in total amino acid content in Synechocystis and a 1.42-fold increase in Chlorella. Total fatty acids content increased by 1.92-fold in Synechocystis and by 2.16-fold in Chlorella. Overall, the study demonstrated the effectiveness of exogenously adding IAA as a strategy for enhancing the accumulation of microalgae biomass and biomolecules. These findings contribute to the advancement of microalgae-based technologies, opening new avenues to produce economically important compounds derived from microalgae.
Open AccessExploring Exogenous Indole-3-acetic Acid’s Effect on the Growth and Biochemical Profiles of Synechocystis sp. PAK13 and Chlorella variabilis
Microalgae have garnered scientific interest for their potential to produce bioactive compounds. However, the large-scale industrial utilization of microalgae faces challenges related to production costs and achieving optimal growth conditions. Thus, this study aimed to investigate the potential role of exogenous indole-3-acetic acid (IAA) application in improving the growth and production of bioactive metabolites in microalgae. To this end, the study employed different concentrations of exogenously administered IAA ranging from 0.36 µM to 5.69 µM to assess its influence on the growth and biochemical composition of Synechocystis and Chlorella. IAA exposure significantly increased IAA levels in both strains. Consequentially, improved biomass accumulation in parallel with increased total pigment content by approximately eleven-fold in both strains was observed. Furthermore, the application of IAA stimulated the accumulation of primary metabolites. Sugar levels were augmented, providing a carbon source that facilitated amino acid and fatty acid biosynthesis. As a result, amino acid levels were enhanced as well, leading to a 1.55-fold increase in total amino acid content in Synechocystis and a 1.42-fold increase in Chlorella. Total fatty acids content increased by 1.92-fold in Synechocystis and by 2.16-fold in Chlorella. Overall, the study demonstrated the effectiveness of exogenously adding IAA as a strategy for enhancing the accumulation of microalgae biomass and biomolecules. These findings contribute to the advancement of microalgae-based technologies, opening new avenues to produce economically important compounds derived from microalgae.
- Open Access
- 28 June 2022
- Published by MDPI AG in Marine Drugs
- Vol. 20 (7) , 425
Therapeutic Intervention with Dietary Chitosan Nanoparticles Alleviates Fish Pathological and Molecular Systemic Inflammatory Responses against Infections
Marine bio-sourced chitosan nanoparticles (CSNP) are antimicrobial and immunomodulatory agents beneficial for fish medicine. Herein, dietary CSNP was investigated for the amelioration of the systemic inflammatory responses of an induced fish model. One hundred and forty-four rainbow trout were assigned to one pathogen-free and non-supplemented group (negative control), and three challenged groups: non-supplemented (positive control), CSNP-preventive, and CSNP-therapeutic. After a feeding experiment extended for 21 days, the organosomatic indices (OSI) and molecular aspects were assessed. After a challenge experiment extended for further 28 days, CSNP-therapeutic intervention was assessed on fish survival and systemic inflammatory responses on pathology, histo-morphology, and molecular aspects. With CSNP administration, OSI nonsignificantly decreased and the relative expression of targeted inflammatory-mediator genes was significantly increased. The CSNP-therapeutic fish showed an RPS of 80% as compared to the positive control group, and CSNP-therapeutic administration retained the highest gene expression augmentation up to 28 days after the challenge. Notably, the splenic reticulin fibers framework of the CSNP-therapeutic group retained the highest integrity among the groups during the infection. After recovery, reticulin fibers density in the CSNP-therapeutic samples was significantly higher than in the negative control group, which indicates high innate immunity. Thus, CSNP showed promising biotherapeutic features enhancing fish resistance against infections.
- 28 June 2022
- Published by MDPI AG in Marine Drugs
- Vol. 20 (7) , 425
Open AccessTherapeutic Intervention with Dietary Chitosan Nanoparticles Alleviates Fish Pathological and Molecular Systemic Inflammatory Responses against Infections
Marine bio-sourced chitosan nanoparticles (CSNP) are antimicrobial and immunomodulatory agents beneficial for fish medicine. Herein, dietary CSNP was investigated for the amelioration of the systemic inflammatory responses of an induced fish model. One hundred and forty-four rainbow trout were assigned to one pathogen-free and non-supplemented group (negative control), and three challenged groups: non-supplemented (positive control), CSNP-preventive, and CSNP-therapeutic. After a feeding experiment extended for 21 days, the organosomatic indices (OSI) and molecular aspects were assessed. After a challenge experiment extended for further 28 days, CSNP-therapeutic intervention was assessed on fish survival and systemic inflammatory responses on pathology, histo-morphology, and molecular aspects. With CSNP administration, OSI nonsignificantly decreased and the relative expression of targeted inflammatory-mediator genes was significantly increased. The CSNP-therapeutic fish showed an RPS of 80% as compared to the positive control group, and CSNP-therapeutic administration retained the highest gene expression augmentation up to 28 days after the challenge. Notably, the splenic reticulin fibers framework of the CSNP-therapeutic group retained the highest integrity among the groups during the infection. After recovery, reticulin fibers density in the CSNP-therapeutic samples was significantly higher than in the negative control group, which indicates high innate immunity. Thus, CSNP showed promising biotherapeutic features enhancing fish resistance against infections.
- Open Access
- 8 January 2021
- Published by MDPI AG in Marine Drugs
- Vol. 19 (1) , 22
Synergistic Effect of Biosynthesized Silver Nanoparticles and Natural Phenolic Compounds against Drug-Resistant Fish Pathogens and Their Cytotoxicity: An In Vitro Study
Fish pathogens causing disease outbreaks represent a major threat to aquaculture industry and food security. The aim of the presented study is to develop safe and effective bioactive agents against two bacterial isolates: Aeromonas hydrophila and Pseudomonas fluorescens. We employed a broth microdilution method to investigate the antibacterial effect of biosynthesized silver nanoparticles (AgNPs); rutin, a natural flavonoid extracted from Ruta graveneoles; and heliomycin, a secondary metabolite produced by marine actinomycetes AB5, as monotherapeutic agents. Moreover, AgNPs in combination with rutin (AgNP + R) and heliomycin (AgNPs + H) were examined for their synergistic effect. The cytotoxic effect of individual bioactive compounds and in combination with AgNPs was investigated on epithelioma papulosum cyprini (EPC) fish cell lines. Individual treatment of AgNPs, rutin, and heliomycin exhibited a dose-dependent antimicrobial activity against A. hydrophila and P. fluorescens. Rutin minimum inhibitory concentration (MIC) showed the lowest cytotoxicity when tested on EPC cell lines, while heliomycin MIC was highly cytotoxic. Combined subtherapeutic doses of AgNPs + R and AgNPs + H displayed additive and synergistic effects against A. hydrophila and P. fluorescens, respectively, with improved results and relative safety profile. The study findings demonstrate that a combination of AgNPs and natural bioactive compounds may represent novel therapeutics fighting fish pathogens potentially affecting the fish farming industry.
- 8 January 2021
- Published by MDPI AG in Marine Drugs
- Vol. 19 (1) , 22
Open AccessSynergistic Effect of Biosynthesized Silver Nanoparticles and Natural Phenolic Compounds against Drug-Resistant Fish Pathogens and Their Cytotoxicity: An In Vitro Study
Fish pathogens causing disease outbreaks represent a major threat to aquaculture industry and food security. The aim of the presented study is to develop safe and effective bioactive agents against two bacterial isolates: Aeromonas hydrophila and Pseudomonas fluorescens. We employed a broth microdilution method to investigate the antibacterial effect of biosynthesized silver nanoparticles (AgNPs); rutin, a natural flavonoid extracted from Ruta graveneoles; and heliomycin, a secondary metabolite produced by marine actinomycetes AB5, as monotherapeutic agents. Moreover, AgNPs in combination with rutin (AgNP + R) and heliomycin (AgNPs + H) were examined for their synergistic effect. The cytotoxic effect of individual bioactive compounds and in combination with AgNPs was investigated on epithelioma papulosum cyprini (EPC) fish cell lines. Individual treatment of AgNPs, rutin, and heliomycin exhibited a dose-dependent antimicrobial activity against A. hydrophila and P. fluorescens. Rutin minimum inhibitory concentration (MIC) showed the lowest cytotoxicity when tested on EPC cell lines, while heliomycin MIC was highly cytotoxic. Combined subtherapeutic doses of AgNPs + R and AgNPs + H displayed additive and synergistic effects against A. hydrophila and P. fluorescens, respectively, with improved results and relative safety profile. The study findings demonstrate that a combination of AgNPs and natural bioactive compounds may represent novel therapeutics fighting fish pathogens potentially affecting the fish farming industry.
- Open Access
- 1 February 2018
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 14, 631-640
Pediatric-onset multiple sclerosis in Egypt: a multi-center registry of 186 patients
Introduction: Although the frequency of pediatric-onset multiple sclerosis (POMS) has increased in recent decades, it is still highly uncommon, which creates a need for the involvement of more registries from various clinical centers. Objective: To characterize the demographic, clinical, and paraclinical features of Egyptian patients with POMS. Patients and methods: A retrospective chart review study was undertaken on 237 Egyptian patients with demyelinating events which started before the age of 18 years who attended one of five tertiary referral centers in Cairo, Egypt. Results: Multiple sclerosis was diagnosed in 186 patients, 47 (25.27%) patients had disease onset before the age of 12 years; “early-onset pediatric multiple sclerosis (EOPMS)”. The mean age of disease onset was (14.13±2.49 years), with a female:male ratio of 1.62:1, none of the enrolled patients had a primary progressive course (PPMS), whereas 10 patients (5.38%) had a secondary progressive form. Approximately two-thirds of the patients had monofocal disease onset, and less than 10% presented with encephalopathy; most of them had EOPMS. Motor weakness was the presenting symptom in half of the patients, whereas cerebellar presentation was detected in 34.95%, mainly in EOPMS. Seizures (not related to encephalopathy) were more frequent in those with EOPMS. Initial brain magnetic resonance images were positive in all patients, with detected atypical lesions in 29.03%, enhanced lesions in 35.48%, black holes in 13.98%, and infratentorial in 34.41%. Cervical cord involvement was found in 68.28%. More than two-thirds of the patients received either immunomodulatory or immunosuppressant (IS) treatment throughout their disease course, and about half of them received their treatment within the first year from symptoms onset, with a more favorable outcome, and patients with highly active disease received natalizumab, fingolimod, or other IS. Conclusion: The results from this registry – the largest for MS in the Arab region to date – are comparable to other registries. Immunomodulatory therapies in POMS are well tolerated and efficacious and they can improve the long-term outcome in children.
- 1 February 2018
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 14, 631-640
Open AccessPediatric-onset multiple sclerosis in Egypt: a multi-center registry of 186 patients
Introduction: Although the frequency of pediatric-onset multiple sclerosis (POMS) has increased in recent decades, it is still highly uncommon, which creates a need for the involvement of more registries from various clinical centers. Objective: To characterize the demographic, clinical, and paraclinical features of Egyptian patients with POMS. Patients and methods: A retrospective chart review study was undertaken on 237 Egyptian patients with demyelinating events which started before the age of 18 years who attended one of five tertiary referral centers in Cairo, Egypt. Results: Multiple sclerosis was diagnosed in 186 patients, 47 (25.27%) patients had disease onset before the age of 12 years; “early-onset pediatric multiple sclerosis (EOPMS)”. The mean age of disease onset was (14.13±2.49 years), with a female:male ratio of 1.62:1, none of the enrolled patients had a primary progressive course (PPMS), whereas 10 patients (5.38%) had a secondary progressive form. Approximately two-thirds of the patients had monofocal disease onset, and less than 10% presented with encephalopathy; most of them had EOPMS. Motor weakness was the presenting symptom in half of the patients, whereas cerebellar presentation was detected in 34.95%, mainly in EOPMS. Seizures (not related to encephalopathy) were more frequent in those with EOPMS. Initial brain magnetic resonance images were positive in all patients, with detected atypical lesions in 29.03%, enhanced lesions in 35.48%, black holes in 13.98%, and infratentorial in 34.41%. Cervical cord involvement was found in 68.28%. More than two-thirds of the patients received either immunomodulatory or immunosuppressant (IS) treatment throughout their disease course, and about half of them received their treatment within the first year from symptoms onset, with a more favorable outcome, and patients with highly active disease received natalizumab, fingolimod, or other IS. Conclusion: The results from this registry – the largest for MS in the Arab region to date – are comparable to other registries. Immunomodulatory therapies in POMS are well tolerated and efficacious and they can improve the long-term outcome in children.